Posts by: Alejandra Viviescas, PhD.

Alejandra Viviescas, PhD.

Alejandra has a PhD in Genetics from São Paulo State University (UNESP) and is currently working as a scientific writer, editor, and translator. As a writer for BioNews, she is fulfilling her passion for making scientific data easily available and understandable to the general public. Aside from her work with BioNews, she also works as a language editor for non-English speaking authors and is an author of science books for kids.

October 23, 2019October 24, 2019

Daiichi Sankyo Files New Drug Application for DS-8201 in Japan

News

Daiichi Sankyo has submitted an application to Japanese regulatory authorities asking that its investigational therapy trastuzumab deruxtecan (DS-8201) be approved as a treatment for people with HER2-positive metastatic breast cancer. ... Read more

September 30, 2019

First Patients Dosed in Phase 1 Trial Testing ARV-471 in Advanced, ER-Positive Breast Cancer

News

The first patients have been dosed in a Phase 1 trial evaluating Arvinas‘ experimental therapy ARV-471 for locally-advanced or metastatic ER-positive, HER2-negative breast cancer. Approximately 80% of newly-diagnosed breast cancers ... Read more

July 17, 2019

Trilaciclib-Chemo Combo Extends Lives of Triple-negative Breast Cancer Patients, Preliminary Phase 2 Findings Show

News

Trilaciclib, a treatment that protects the bone marrow from the damaging effects of chemotherapy, significantly extends the lives of women with metastatic triple-negative breast cancer receiving a chemotherapy regimen of ... Read more

April 22, 2019

Antibiotic in Long Use for Leprosy, Clofazimine, May Treat Triple-negative Breast Cancer, Mouse Study Suggests

News

Clofazimine, an antibiotic long used for treating leprosy and tuberculosis, may be repurposed as a promising potential treatment for triple-negative breast cancer, a study in mice suggests. The treatment targets the ... Read more

February 13, 2019

Changes in Gene Expression May Hint at Relapse Risk in ER-positive Patients on Hormone Therapy, Study Finds

News

Specific changes in gene expression might help to predict the risk of relapse in estrogen receptor (ER)-positive breast cancer patients under hormone therapy, a study reports. The study, “Molecular changes ... Read more

February 4, 2019

Breast Cancers Diagnosed Within 10 Years of Pregnancy Have Higher Risk of Metastasis, Study Shows

News

Women diagnosed with breast cancer up to 10 years after giving birth have a higher risk of metastasis than childless women of the same age, a study says. The study, ... Read more

January 7, 2019

Circulating Tumor Cell Numbers May Help Decide Best Therapy for Metastatic Breast Cancer, Phase 3 Trial Shows

News

The number of circulating tumor cells (CTCs) could help doctors choose between hormone therapy or chemotherapy for the first-line treatment of metastatic breast cancer patients whose tumors produce estrogen receptor ... Read more

November 5, 2018

Ibrance-Faslodex Combo Improves Survival of Advanced Breast Cancer Patients, Phase 3 Trial Shows

News

Adding Pfizer’s Ibrance (palbociclib) to standard treatment Faslodex (fulvestrant) significantly extended the survival of advanced breast cancer patients in a Phase 3 clinical trial, researchers report. Called PALOMA-3, the trial (NCT01942135) specifically ... Read more